 | ||||
For Families...Three pharmaceutical companies are developing medications which target mGluR5 for children and adults who have Fragile X.One of the three compounds, Novartis AFQ056, is now in Phase IIb clinical trials. Medical centers in the US, Europe, Australia, and Canada are enrolling men and women age 18-45 with Fragile X syndrome in this trial, and trials for ages 12-17 are expected to begin soon. More about the trial Why mGluR5? | For Researchers...FRAXA Investigators MeetingSeptember 18-21, 2011 Southbridge, MA Hotel and Conference Center Register or Learn more New Autism iPSC Resource includes Fragile X An NIH-funded Autism induced pluripotent stem cell (iPSC) Biorepository has been established. Fibroblast and iPSC lines available from patients with FMR1 gene full- and pre-mutations. Learn more RNA Binding Proteins in Neurological Disease Satellite Symposium at SfN Annual Meeting Learn more | |||
| FRAXA Research Foundation, phone: 978 462-1866, web: fraxa.org, email: kclapp@fraxa.org What is Fragile X? About FRAXA | ||||
| If you no longer want updates from FRAXA, please accept our apologies and reply to this message with "Unsubscribe" in the subject line or click: Unsubscribe |
| FRAXA Research Foundation 45 Pleasant St. Newburyport, MA 01950 US Read the VerticalResponse marketing policy. |  |
Post a Comment